LLY - Eli Lilly and Company logo

Eli Lilly and Company

LLY

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceuticals focusing on cardiometabolic health, oncology, immunology, and neuroscience. Key products include insulin for diabetes, cancer therapies, and treatments for autoimmune disorders.

⚕️ Healthcare NYSE Listed 1978 $ USD
$1,000 invested 30 years ago →$79,462today

Score Overview

1 Year
Score
Net Growth33.62%
Net TrendGrew
Net Income Consistency—
Rev Growth32.65%
Rev TrendGrew
Revenue Consistency—
5 Years
Score8.9
Net Growth394.11%
Net Trend80%
Net Income Consistency—
Rev Growth205.32%
Rev TrendEvery year
Revenue Consistency—
10 Years
Score
Net Growth10x
Net Trend60%
Net Income Consistency
Rev Growth307.41%
Rev Trend90%
Revenue Consistency
20 Years
Score6.7
Net Growth10x
Net Trend60%
Net Income Consistency
Rev Growth451.03%
Rev Trend85%
Revenue Consistency
30 Years
Score
Net Growth18x
Net Trend57%
Net Income Consistency
Rev Growth12x
Rev Trend87%
Revenue Consistency
All Time
Score
Net Growth53x
Net Trend61%
Net Income Consistency
Rev Growth26x
Rev Trend85%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Eli Lilly and Company has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.

  • LLY

1996: 25.9% · 2021: 66.4% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 1.42K—
1 Year2025-11-17
$ 1.02K39.39%
5 Years2021-11-17
$ 250.10466.00%
10 Years2016-11-17
$ 66.8121x
20 Years2006-11-17
$ 31.2645x
30 Years1996-11-15
$ 17.8179x
All Time1978-01-13
$ 0.582443x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 86.46B$ 27.57B$ 4.88B
2025$ 65.17B$ 20.64B$ 7.26B
2024$ 45.04B$ 10.59B$ 3.42B
2023$ 34.12B$ 5.24B$ 2.92B
2022$ 28.54B$ 6.24B$ 2.21B
2021$ 28.31B$ 5.58B$ 3.90B
2020$ 24.53B$ 6.19B$ 3.68B
2019$ 22.31B$ 8.31B$ 2.43B
2018$ 21.49B$ 3.23B$ 7.40B
2017$ 19.97B-$ 204M$ 8.03B
2016$ 21.22B$ 2.73B$ 6.03B
2015$ 19.95B$ 2.40B$ 4.45B
2014$ 19.61B$ 2.39B$ 4.82B
2013$ 23.11B$ 4.68B$ 5.39B
2012$ 22.60B$ 4.08B$ 5.68B
2011$ 24.28B$ 4.34B$ 6.89B
2010$ 23.07B$ 5.06B$ 6.72B
2009$ 21.83B$ 4.32B$ 4.49B
2008$ 20.37B-$ 2.07B$ 5.92B
2007$ 18.63B$ 2.95B$ 4.83B
2006$ 15.69B$ 2.66B$ 3.89B
2005$ 14.64B$ 1.97B$ 5.03B
2004$ 13.85B$ 1.81B$ 7.46B
2003$ 12.58B$ 2.56B$ 3.71B
2002$ 11.07B$ 2.70B$ 3.65B
2001$ 11.54B$ 2.78B$ 3.73B
2000$ 10.86B$ 3.05B$ 4.61B
1999$ 10.00B$ 2.72B$ 3.83B
1998$ 9.23B$ 2.09B$ 1.49B
1997$ 7.98B-$ 385M$ 1.94B
1996$ 6.99B$ 1.52B$ 813M
1995$ 6.76B$ 2.29B$ 999M
1994$ 5.71B$ 1.28B$ 536M
1993$ 6.45B$ 480M$ 539M
1992$ 6.16B$ 708M$ 432M
1991$ 5.72B$ 1.31B$ 479M
1990$ 5.19B$ 1.12B$ 350M
1989$ 4.17B$ 939M$ 323M
1988$ 4.06B$ 761M$ 761M
1987$ 3.64B$ 643M$ 1.03B
1986$ 3.72B$ 558M$ 486M
1985$ 3.27B$ 517M$ 406M
LLY - Eli Lilly and Company logo

Eli Lilly and Company fundamental performance

Between 2020 and 2025, revenue grew from $ 24.53B to $ 65.17B and net income grew from $ 6.19B to $ 20.64B. Revenue increased in every one of those 5 years; net income in 4.

Between 2015 and 2025, revenue grew from $ 19.95B to $ 65.17B and net income grew from $ 2.40B to $ 20.64B. Revenue increased in 9 of those 10 years; net income in 6.

Eli Lilly and Company currently holds a 20-year HDB Score of 6.7 out of 10. How the HDB Score is calculated.

Membership

Continue LLY’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies